Skip to content
DE

Thymosin Peptides: Mechanisms, Clinical Evidence, and Regulatory Status

Clinical review pending

How thymosin alpha-1, beta-4, TB-500, and prothymosin alpha differ: hepatitis, sepsis, corneal research, safety, and current US regulatory limits.

A balance holds a bead chain on one side and a clear lens on the other.

What can thymosin peptides do medically? The answer depends on the molecule. Thymosin alpha-1 influences immune responses, thymosin beta-4 regulates cell movement and tissue repair, and prothymosin alpha works mainly in the cell nucleus. Their shared name covers substances with very different biology. Just as important is where a finding comes from: cells, animal models, or clinical studies.

This article provides general information and does not replace medical advice, diagnosis, or treatment. Regulatory information reflects the cited sources reviewed on October 31, 2026, and mainly concerns the United States. None of the thymosin peptides discussed here has FDA approval according to those sources. International drug approvals and conditional enforcement discretion for compounding are separate matters.

Key points

  • The thymosin family includes biologically distinct substances. Evidence about one cannot stand in for evidence about another. None of the peptides discussed here has established FDA approval. In Singapore, prescription Zadaxin, or thymalfasin, is registered for chronic hepatitis B alone or with interferon and for chronic hepatitis C with interferon. That product information does not list a cancer indication.
  • Randomized studies of Tα1 have examined hepatitis and sepsis, including a small HCV pilot study and the large phase 3 TESTS trial. The Tβ4 eye solution RGN-259 reached phase 3, but SEER-1 ended after enrolling only 18 participants. Prothymosin alpha remains preclinical in the research discussed here.
  • Removal of Tα1 and TB-500 from FDA Category 2 following withdrawal of their nominations in April 2026 was not approval. The nonbinding committee recommendation for TB-500 on July 23, 2026, is also distinct from approval. The HHS policy published on October 30, 2026, describes enforcement discretion under narrow conditions for TB-500 acetate administered subcutaneously or intramuscularly. It is neither FDA approval nor final inclusion on the 503A bulks list. Requirements include a patient-specific prescription, a single active ingredient, qualified manufacturing and documented quality testing, and reporting of serious adverse events and product quality problems. The policy does not broadly cover online products, full-length thymosin beta-4, thymosin alpha-1, or prothymosin alpha.
  • PubChem CID 16130571 describes thymalfasin. A database entry is not approved prescribing information.
  • Tα1 influences dendritic cells and T-cell responses through Toll-like receptor pathways. Tβ4 regulates actin and cell migration. Prothymosin alpha influences chromatin in the nucleus.
  • In a small hepatitis B study, the complete virological response rate 18 months after enrollment was 40.6% following 26 weeks of treatment versus 9.4% without treatment. This meant clearance of HBV DNA and HBeAg, not demonstrated cure. TESTS, by contrast, found no established survival benefit in sepsis. Ophthalmic findings for Tβ4 are promising but still limited. Source 1 Source 2 Source 3 Source 4 Source 5 Source 6

The thymus: Why researchers expected thymus extracts to affect immunity

The thymus is a small, two-lobed organ in the upper chest behind the breastbone. Its main job is to train and mature T lymphocytes. Precursor cells migrate from the bone marrow into the thymus, where they undergo positive and negative selection. The result is a population of functional T cells that normally tolerates the body’s own tissues.

The thymus is most active during childhood and early adolescence. After puberty, it begins to undergo involution: fat gradually replaces functional thymic tissue, and production of naive T cells falls throughout adulthood. “Naive” means that these T cells have not yet encountered their matching antigen.

In a 2020 review in Immunity and Ageing, Thomas, Wang, and Su described two major consequences of this age-related shrinkage. Fewer naive T cells are produced, and central tolerance becomes less effective. Central tolerance is the process that removes immune cells directed against the body during their maturation. Autoreactive and senescent, functionally aged immune cells can consequently accumulate and promote chronic low-grade inflammation. In Nature Immunology in 2021, Mittelbrunn and Kroemer identified thymic involution as a central feature of T-cell aging. They linked declining thymic function to greater susceptibility to infection and cancer and to weaker vaccine responses. Source 1 Source 2

For immunologists in the 1960s, this raised an appealing question: could an organ that directs immune development release hormones that maintain immune function throughout life? If those hormones could be extracted and administered, perhaps they could restore immune function in people with immunodeficiency.

Goldstein and colleagues began testing that hypothesis. In a personal historical account published in the Annals of the New York Academy of Sciences in 2007, Goldstein described how the team first purified a biologically active fraction from calf thymus. They called it “thymosin fraction 5” and first reported it in the Proceedings of the National Academy of Sciences in 1966. In mice whose thymus had been removed, the fraction appeared to restore T-cell function, supporting the hormone hypothesis. Source 1 Source 2

What remained unclear was which components of fraction 5 were responsible.

Why the name “thymosin” does not imply a shared structure

The name thymosin came before a full biochemical understanding of the peptides grouped under it. When Goldstein, Slater, and White purified the material they called thymosin in 1966, they described a heterogeneous mixture. They had not yet identified a single, clearly defined molecule.

Low, Thurman, McAdoo, and colleagues showed in the Journal of Biological Chemistry in 1979 that thymosin fraction 5 could be separated into chemically different molecules with fundamentally different biological activities. Thymosin alpha-1 contains 28 amino acids and was 10 to 1,000 times as potent as the unpurified fraction in biological tests of T-cell function. The beta-1 polypeptide isolated from the same material showed no measurable activity in those tests. Source 1

Goldstein and Badamchian accordingly described thymosins in Expert Opinion on Biological Therapy in 2004 as a family of biochemically and functionally distinct polypeptides. “Family” is a historical classification here: the peptides came from the same tissue extract but do not share a receptor, signaling pathway, or basic molecular structure. Huff, Müller, Otto, Netzker, and Hannappel explained this distinction for beta-thymosins in the International Journal of Biochemistry and Cell Biology in 2001. These peptides bind actin and keep it temporarily available; their structure and function differ from those of thymosin alpha-1 and the prothymosin series. Source 1 Source 2

That distinction has a practical consequence when reading studies. Findings about thymosin alpha-1 cannot be transferred to thymosin beta-4, or vice versa. The first question is which substance or subfraction was actually studied.

Thymosin alpha-1: The family member with international clinical approvals

Thymosin alpha-1, abbreviated Tα1, is the best-characterized and most clinically developed member of the thymosin family. It contains 28 amino acids and corresponds to the N-terminal fragment of prothymosin alpha, a segment at its amino end.

Tα1 is marketed as Zadaxin. Singapore’s government drug formulary documents a specific current approval: Zadaxin 1.6 mg, registration SIN07483P, is registered for chronic hepatitis B alone or with interferon and for chronic hepatitis C with interferon. The product information updated on October 9, 2026, does not list an oncology indication. This is a country-specific approval, not FDA approval. Source 1

Mechanism: Toll-like receptor signaling and dendritic cell activation

Thymosin alpha-1 does not act directly on T cells in the same way as a cytokine, an immune signaling molecule. A central part of its proposed mechanism involves activating dendritic cells. These cells recognize and present antigens, helping to direct the subsequent immune response.

Romani, Bistoni, Gaziano, and colleagues at the University of Perugia showed in Blood in 2004 that Tα1 activates dendritic cells through Toll-like receptor pathways. A pathway dependent on myeloid differentiation factor 88, or MyD88, is particularly involved. This stimulates interleukin-12 production and favors the development of naive T cells into Th1 cells, which support cellular defenses against pathogens. The study particularly examined defenses against fungal infection when immune function was impaired. Source 1

This mechanism helps explain why Tα1 has been studied in different forms of weakened immunity. The hypothesis is that it supports upstream control processes in innate immunity rather than simply replacing one immune signal. Those processes, in turn, guide the adaptive, targeted immune response. Whether that produces a clinical benefit in a particular disease requires a separate test.

Hepatitis B: Historical studies and a clinical signal

Chronic hepatitis B is one of the clinical applications studied for thymosin alpha-1. Chien, Liaw, Chen, Yeh, and Sheen enrolled 98 patients in a randomized controlled study published in Hepatology in 1998. They compared 26 or 52 weeks of treatment with an untreated control group. Participants received 1.6 mg subcutaneously twice a week. The common assessment point was 18 months after enrollment, not 18 months after the end of each treatment.

At 18 months, 40.6% of the 26-week group had a complete virological response, compared with 9.4% of controls, p = 0.004. The rate in the 52-week group was 26.5%; its comparison with controls was not significant, p = 0.068. The endpoint meant clearance of serum HBV DNA and HBeAg. No responder lost HBsAg, so these figures do not demonstrate cure. At the end of treatment, the groups had not shown a clear difference. No significant side effects were reported in this small study, but the small groups limit both the precision of its estimates and its safety assessment. Source 1

A meta-analysis by Yang, Zhao, Zhong, and colleagues, published in Antiviral Research in 2008, brought together four randomized controlled studies involving 199 participants. These compared thymosin alpha-1 with interferon-alpha for chronic hepatitis B. Virological responses were comparable at the end of treatment. During follow-up, Tα1 showed a trend toward additional new responses, whereas relapses were more common with interferon.

The review points to small individual studies, differences among them, and changes in hepatitis B treatment over time. Historical comparisons with interferon do not establish how Tα1 compares with today’s treatments. The paper documents a clinical signal, but it is not a current guideline and does not support a general first-line recommendation. Source 1

For hepatitis C, Andreone, Gramenzi, Cursaro, and colleagues compared interferon-alpha 2b plus thymosin alpha-1 with interferon-alpha 2b alone in a randomized controlled pilot study published in the Journal of Viral Hepatitis in 2004. It enrolled 41 previously untreated people with chronic HCV infection: 22 received combination treatment and 19 received monotherapy. Six months of treatment were followed by six months of follow-up.

Virological response rates were significantly higher with combination treatment at the end of treatment, p = 0.03. After six months of follow-up, however, sustained response rates did not differ between groups. The small sample limits the conclusions that can be drawn from this pilot finding. Source 1

Sepsis: Mixed and evolving evidence

Thymosin alpha-1 has been studied extensively in severe sepsis. The rationale was that sepsis can cause profound immunosuppression: lymphocytes decline in number and become functionally exhausted, monocytes show reduced HLA-DR expression, and effective adaptive immune responses fail to develop. HLA-DR is a cell-surface marker involved in antigen presentation. Researchers hypothesized that Tα1 might restore dendritic cell activation and Th1 signaling, reversing this “immune paralysis” and improving survival.

Wu and colleagues published ETASS in Critical Care in 2013. This multicenter, single-blind, randomized controlled trial enrolled 361 patients from six Chinese hospitals. It compared thymosin alpha-1 plus standard care with standard care alone. Within 28 days, 26.0% of patients in the Tα1 group died, compared with 35.0% of controls.

The statistical result was not clear-cut. The primary unstratified analysis gave p = 0.062, whereas the log-rank comparison of survival curves gave p = 0.049. Findings about immune recovery, particularly improved HLA-DR expression on monocytes, were more consistently significant than the mortality results. Source 1

The larger TESTS trial by Wu, Pei, Guan, and colleagues appeared in The BMJ in January 2025. This multicenter, double-blind, placebo-controlled phase 3 trial randomized 1,106 adults with sepsis at 22 Chinese centers: 552 to Tα1 and 554 to placebo. Its modified intention-to-treat analysis included 1,089 people, 542 receiving Tα1 and 547 receiving placebo. Subcutaneous treatment was given every 12 hours for seven days.

Within 28 days, 127 of 542 people receiving Tα1 died, 23.4%, compared with 132 of 547 receiving placebo, 24.1%. The official correction of May 30, 2025, gives a hazard ratio of 0.97 with a 95% confidence interval of 0.76 to 1.24 for this endpoint. The originally published values of 0.99 and 0.77 to 1.27 are outdated. The corrected estimate still shows no established survival benefit. Its interval allows for a possible benefit as well as a possible disadvantage. Secondary outcomes and safety outcomes likewise showed no clear group difference. Source 1 Source 2

The authors found no clear evidence of reduced all-cause mortality within 28 days. Subgroup analyses, including those involving people age 60 or older and people with diabetes, are exploratory. Given the multiple comparisons, they should not be read as confirmed treatment benefits in those groups; the paper applied a stricter Bonferroni threshold for this purpose. Such differences need prospective testing.

Before TESTS, Liu, Wang, and colleagues had already described limitations in earlier sepsis trials in a 2016 systematic review in BMC Infectious Diseases. They rated the evidence as low quality because of small samples, methodological differences, and potential bias. That made a large, double-blind study such as TESTS necessary. Its negative primary result carries more weight clinically than the earlier positive signals. Source 1

Cancer immunology: Research into adjunctive treatment

Costantini, Bellet, Pariano, Renga, and colleagues reassessed thymosin alpha-1 in cancer therapy in Frontiers in Oncology in 2019. Their review addressed melanoma, hepatocellular carcinoma, and lung cancer. Tα1 was investigated both as an immune adjunct to chemotherapy and as a potential partner for checkpoint-inhibitor immunotherapy. Source 1

The idea is that activating dendritic cells and promoting Th1 responses could turn immunologically “cold” tumors into “hot” ones. Cold tumors contain few effective infiltrating T cells; hot tumors have greater immune cell activity and might respond better to blockade of the PD-1 or CTLA-4 immune checkpoints. This remains an exploratory therapeutic concept. A plausible mechanism and early clinical observations do not establish effectiveness for every cancer or make a combination an approved treatment.

COVID-19: A meta-analysis does not support routine use

Interest in Tα1 for COVID-19 grew from immunological reasoning similar to that behind its use in sepsis. Severe SARS-CoV-2 infection can involve lymphopenia, monocyte dysfunction, and a suppressed Th1 response. Shang, Zhang, Ren, and colleagues reviewed nine studies involving 5,352 patients in International Immunopharmacology in 2023: 1,152 received Tα1 and 4,200 were controls. Seven studies were retrospective cohorts and only two were randomized trials, so the evidence was predominantly observational. Source 1

Across the pooled study population, thymosin alpha-1 had no statistically significant effect on mortality. The relative risk, or RR, was 1.03, with a 95% confidence interval of 0.60 to 1.75 and p = 0.92. An RR of 1 represents no difference between groups. Individual study results varied considerably, with heterogeneity of I² = 90%.

Prespecified subgroup analyses found lower mortality among severely or critically ill patients: RR 0.66, 95% confidence interval 0.57 to 0.76, p < 0.0001, and I² = 0%. A similar signal appeared in study groups with an average age over 60: RR 0.68, 95% confidence interval 0.58 to 0.78, p < 0.0001. However, the age subgroups were based on the average age of whole study groups, not a randomized test in individual older patients. The difference between the age subgroups was not significant, interaction p = 0.36. These findings do not establish a special benefit for people over 60.

The authors nevertheless concluded that their findings did not support routine use in hospitalized adults with COVID-19. The subgroup findings need prospective confirmation. On the basis of this meta-analysis, thymosin alpha-1 cannot be recommended as a routine COVID-19 treatment.

Approval and availability

In Expert Opinion on Biological Therapy in 2009, Goldstein and Goldstein traced thymosin alpha-1’s clinical development from laboratory discovery to international approvals. Accounts associated with this review describe Zadaxin approvals for hepatitis B and hepatitis C in more than 35 countries. That country count is a historical statement about its development, not a verified worldwide approval list for 2026. The current Singapore product information linked above documents specific hepatitis indications. Source 1

According to the sources reviewed here, Tα1 has no FDA approval. Clinical trials or individually authorized expanded-access arrangements can provide research access to unapproved drugs. That does not establish general availability or an exhaustive list of every legal possibility. The October 2026 HHS policy does not cover Tα1. US information also does not determine approval or availability in Germany.

Thymosin beta-4: The actin-binding peptide

Thymosin beta-4, or Tβ4, is a naturally occurring 43-amino-acid peptide encoded by the TMSB4X gene. It is not an immune hormone. Its main role is to regulate the dynamics of the actin cytoskeleton. Tβ4 binds strongly to G-actin, the globular individual subunit of the protein, maintaining an intracellular reserve of building blocks that can assemble into filamentous F-actin. Compound identity matters: PubChem CID 16132341 is timbetasin, full-length Tβ4, whereas CID 16130571 is thymalfasin, Tα1. CID 16129704, also present in the reference list, concerns bivalirudin and is not evidence about a thymosin. Source 1 Source 2

When a cell receives a signal to migrate or repair tissue, bound actin is released and incorporated into structures such as lamellipodia and stress fibers. These structures enable or support cell movement.

In the International Journal of Biochemistry and Cell Biology in 2001, Huff and colleagues described beta-thymosins as the main intracellular peptides that bind and temporarily store G-actin. This matters for tissue repair because cell migration is necessary for wound healing. Fibroblasts, endothelial cells, and keratinocytes must reach the injury and move through the wound bed. Their speed and efficiency partly depend on cytoskeletal dynamics regulated by Tβ4. Source 1

Goldstein, Hannappel, and Kleinman expanded this picture in Trends in Molecular Medicine in 2005. They described Tβ4 as an actin-binding peptide involved in tissue repair through several pathways. Alongside its actin-buffering role, the literature describes anti-inflammatory effects, promotion of new blood vessels, and cell-survival signaling. Several different structural regions of the peptide appear to contribute to these effects beyond the cytoskeleton. Source 1

Heart regeneration: Foundational preclinical work

An influential preclinical finding came from a study by Bock-Marquette, Saxena, White, Dimaio, and Srivastava published in Nature in 2004. After surgical blockage of a coronary artery in mice, thymosin beta-4 treatment promoted the migration and survival of heart muscle cells. It activated integrin-linked kinase and downstream Akt survival signaling. Heart function also improved after the experimentally induced heart attack. Source 1

The finding attracted particular interest because heart muscle cells are largely postmitotic: they rarely divide. The possibility that a naturally occurring peptide could stimulate repair in infarcted heart muscle drew substantial research interest in heart regeneration. Later work also showed that Tβ4 can mobilize adult progenitor cells of the epicardium, the heart’s outer layer.

The findings about repair after a heart attack remain preclinical. The human cardiac evidence considered here is limited and preliminary.

Corneal healing: Moving toward human trials

Eye disease is one of the most advanced areas of thymosin beta-4’s clinical development. In Experimental Eye Research in 2002, Sosne, Szliter, Barrett, Kernacki, Kleinman, and Hazlett showed in mice that topical Tβ4 accelerated restoration of the corneal surface after an alkali injury and reduced expression of inflammatory signaling molecules. This preclinical work provided a mechanistic foundation for later clinical development. Source 1

In Expert Opinion on Biological Therapy in 2018, Sosne described the path from preclinical discovery to phase 2 and phase 3 trials in dry eye and neurotrophic keratopathy. Neurotrophic keratopathy is a corneal disease in which impaired nerve supply interferes with healing. This approach is therefore among the more advanced clinical research programs within the thymosin family. Source 1

RGN-259, a 0.1% Tβ4 eye solution, reached phase 3 in neurotrophic keratopathy. SEER-1 ended early after enrolling 18 people. After four weeks, the cornea had healed in 6 of 10 people receiving RGN-259 and 1 of 8 receiving placebo. Fisher’s exact test gave p = 0.0656, missing the usual significance threshold, whereas a different test, chi-square, gave p = 0.04. This small, prematurely ended experiment offers an interesting signal rather than a robustly confirmed efficacy result. SEER-2 is registered as another phase 3 study; no current recruitment status is asserted here. The documents discussed do not establish FDA approval. Source 1 Source 2 Source 3

TB-500: A synthetic fragment with its own identity

TB-500 is a synthetic, acetylated seven-amino-acid fragment of thymosin beta-4, with the sequence Ac-LKKTETQ. It covers the actin-binding region at positions 17 through 23 of the parent molecule, not its entire sequence.

Leeanansaksiri, DeSimone, Huff, Hannappel, and colleagues examined full-length Tβ4 and its N-terminal tetrapeptide Ac-SDKP in mast cells in a paper published in Chemistry and Biodiversity in 2004. Both molecules inhibited mast-cell proliferation, with a maximum effect at 10⁻¹⁴ M. At 10⁻⁸ M, they triggered degranulation, the release of stored cell contents: 57% with Tβ4 and 89% with Ac-SDKP. “M” denotes concentration in moles per liter. Other fragments tested were inactive. Source 1

The study offers limited mechanistic evidence that individual parts of Tβ4 can retain their own biological activity. It is not direct evidence of TB-500’s effectiveness: the Ac-SDKP tested was a different fragment.

Full-length Tβ4 and TB-500 are not interchangeable either. The fragment lacks the rest of the 43-amino-acid peptide, including the C-terminal AGES motif. That alone does not establish that all anti-inflammatory or cardiac effects belong to that motif. What matters is which molecule was actually studied.

Removal of TB-500 from FDA Category 2 after withdrawal of its nomination in April 2026 did not, by itself, authorize compounding. Current interpretation must also consider the later HHS policy. Published on October 30, 2026, that policy describes enforcement discretion under narrow conditions for TB-500 acetate administered subcutaneously or intramuscularly. It is neither FDA approval nor final inclusion on the 503A bulks list. Requirements include a patient-specific prescription, a single active ingredient, qualified manufacturing and documented quality testing, and reporting of serious adverse events and product quality problems. It does not broadly cover online products, full-length thymosin beta-4, thymosin alpha-1, or prothymosin alpha. Source 1 Source 2

Prothymosin alpha: The family member in the nucleus

Prothymosin alpha, or ProTα, is the largest and least clinically discussed member of the thymosin family. The protein contains 111 amino acids, is encoded by the PTMA gene, and is found mainly in the cell nucleus, where it interacts with histone H1. Histones are proteins involved in packaging DNA.

Gómez-Márquez and Rodríguez described prothymosin alpha as a chromatin-remodeling protein in the Biochemical Journal in 1998. Increased ProTα production made chromatin more accessible to micrococcal nuclease and produced nucleosomes containing less histone H1. The authors proposed that ProTα reorganizes chromatin fibers through its interaction with histone H1. It could thereby influence DNA accessibility for transcription, the reading of genes, in actively dividing cells. Source 1

ProTα has different biological tasks depending on its location. Inside cells, it acts as a factor in survival and proliferation, and its expression is closely associated with cell-cycle progression. Outside cells, it appears to have immune-stimulating activities distinct from its nuclear functions. This extracellular biology is less well characterized than that of thymosin alpha-1 or thymosin beta-4.

Samara, Ioannou, and Tsitsilonis examined this dual role in Vitamins and Hormones in 2016. They described prothymosin alpha as both an intracellular mediator of survival and proliferation and an extracellular immune-activating molecule. Its discovery dates back to the original thymosin fraction 5. The review connects those historical experiments with ProTα’s distinct immune functions and explains why a nuclear chromatin-remodeling protein has repeatedly attracted immunological research. Source 1

The sources reviewed here do not show a clinical development program for ProTα comparable in scale to those for Tα1 or Tβ4. Its nuclear and extracellular roles complete the picture of the thymosin family: one shared name encompasses three fundamentally different biological entities.

The following information mainly concerns the United States and sources checked on October 31, 2026. Drug approval, a committee recommendation, inclusion on a bulk-substances list, and enforcement discretion are different processes.

Thymosin alpha-1, Zadaxin, has no FDA approval. Singapore’s current product information documents specific hepatitis B and hepatitis C indications, but it does not list a cancer indication. Historical country counts cannot replace a current country-specific check. Research access has separate requirements. The October 2026 HHS policy covering six peptides does not apply to Tα1.

Thymosin beta-4 and RGN-259 have no FDA approval in the documents reviewed here. SEER-1 ended early after 18 participants; SEER-2 is registered as another phase 3 study, without any assertion here about current recruitment. The HHS policy for TB-500 acetate cannot be extended to full-length Tβ4. Source 1 Source 2

TB-500 was removed from FDA Category 2 after withdrawal of its nomination in April 2026. The historical report on the July 23 meeting describes a nonbinding 8-to-6 recommendation for inclusion for wound healing. Neither removal nor the vote constitutes approval. The October 30, 2026, HHS policy describes enforcement discretion under narrow conditions for TB-500 acetate administered subcutaneously or intramuscularly. It is neither FDA approval nor final inclusion on the 503A bulks list. Requirements include a patient-specific prescription, a single active ingredient, qualified manufacturing and documented quality testing, and reporting of serious adverse events and product quality problems. The policy does not broadly cover online products, full-length thymosin beta-4, thymosin alpha-1, or prothymosin alpha. Source 1 Source 2 Source 3

Prothymosin alpha remains a research substance in the sources discussed here. They establish neither an approved application nor a clinical development program comparable to Tα1 or Tβ4. This is not an exhaustive worldwide registry search.

Important safety information

None of the substances discussed here has FDA approval according to the sources reviewed. Nonetheless, their regulatory circumstances and safety evidence differ substantially.

Singapore documents specific hepatitis indications for Tα1. That does not confer US approval. Withdrawal of the FDA nomination and removal from Category 2 in April 2026 were not authorization for compounding. The October HHS enforcement-discretion policy does not apply to Tα1 either; these sources do not establish a comparable access route.

Thymosin beta-4 has not received FDA approval for any indication. RGN-259, RegeneRx’s ophthalmic formulation, reached phase 3 trials in neurotrophic keratopathy without gaining approval.

TB-500’s removal from Category 2 and the nonbinding committee recommendation in July 2026 are historical steps. The conditional HHS enforcement-discretion policy of October 30 is an additional factor in the subsequent situation. It is not FDA approval or final listing.

The policy covers TB-500 acetate only for subcutaneous or intramuscular administration under its conditions. Requirements include a registered active-ingredient manufacturer with appropriate manufacturing practices and a certificate of analysis; validated testing for identity, purity, potency, endotoxins, heavy metals, microorganisms, and impurities; a patient-specific prescription; a single active ingredient; and reporting of serious events and quality defects. Any drug-delivery device co-packaged with or containing the compounded drug must be an FDA 510(k)-cleared syringe. Other applicable requirements remain in place. Prothymosin alpha is not covered.

Lack of US prescribing information does not mean a substance has no contraindications. Singapore’s current Zadaxin product information lists hypersensitivity to the active ingredient or other components, as well as deliberate immunosuppression, such as after organ transplantation, unless potential benefits clearly outweigh the risks. Access and monitoring must be assessed for the specific product and country. Research products are not substitute medicines.

Particular situations require a substance-specific assessment. Some of the following concerns are theoretical or unresolved, while others, especially those concerning Zadaxin, are explicitly stated in product information:

  • In active cancer, immune-modulating peptides could influence tumor biology.
  • Safety during pregnancy, planned pregnancy, and breastfeeding is unresolved.
  • For concurrent immunosuppressive treatment after organ transplantation, the Zadaxin product information lists deliberate immunosuppression as a contraindication unless potential benefits clearly outweigh the risks. This is not merely a theoretical concern.
  • Additional immune activation is a theoretical concern in autoimmune disease.
  • Serious hypersensitivity to peptide formulations or individual excipients must be considered.
  • Safety in children is not established outside limited international Tα1 programs in pediatric hepatitis B.

Warnings are not interchangeable. Zadaxin has documented contraindications involving hypersensitivity and deliberate immunosuppression. The product information reviewed here does not justify broad frequency labels such as “rare” for every suspected adverse effect. Questions involving autoimmune disease require a separate assessment. Source 1

Published human safety data for thymosin beta-4 and TB-500 are limited. No FDA quality assurance for identity, purity, sterility, or potency is documented here for TB-500 products sold online as research products. Such products should not be equated with medicines that have undergone the relevant testing.

Conditional HHS enforcement discretion for TB-500 acetate explicitly requires quality controls and reporting. It does not certify the safety of arbitrary products sold online. For prothymosin alpha, the sources discussed do not provide a comparable clinical safety evidence base.

Adverse effects must likewise be considered separately for each molecule and formulation. The absence of significant side effects in small Tα1 trials does not rule out rare or long-term risks. Published human data for full-length Tβ4 and TB-500 are limited and cannot be transferred between them. Anecdotes from unregulated use cannot replace controlled safety data or provide reliable frequency estimates.

In sport, the 2026 WADA List prohibits thymosin beta-4 and its derivatives, explicitly including TB-500, at all times under S2. Tα1 is not named there. Among other criteria, S0 requires that no governmental health authority has approved the substance for human therapeutic use; lack of FDA approval alone is insufficient. Given Zadaxin’s documented Singapore approval, broadly classifying Tα1 under S0 for that reason would be wrong. This is not individual clearance for athletes: the relevant anti-doping authorities must assess the specific case. Source 1

Long-term evidence leaves important questions open. The evidence discussed here does not adequately characterize long-term cancer risks, effects on the immune system, or safety in particular populations.

According to the sources considered, none of the thymosin substances discussed has FDA-approved prescribing information in the United States.

Frequently asked questions

What is the difference between thymosin alpha-1 and thymosin beta-4?

Thymosin alpha-1 is a 28-amino-acid immune-modulating peptide. It activates dendritic cells through Toll-like receptor pathways and thereby promotes Th1 immune responses. Thymosin beta-4 contains 43 amino acids, binds actin, and regulates cell migration and tissue-repair processes. The two substances therefore differ biochemically and functionally.

Their shared name comes from their isolation from the same thymus tissue fraction during the 1960s and 1970s. It does not denote a shared structure or function. Goldstein and Badamchian accordingly described thymosins in Expert Opinion on Biological Therapy in 2004 as biochemically and functionally distinct despite their common umbrella term. Source 1

Is thymosin alpha-1, Zadaxin, FDA approved?

No. According to the sources reviewed on October 31, 2026, Tα1 has no FDA approval. In Singapore, Zadaxin is registered for specific hepatitis B and hepatitis C applications. That current product information does not list a cancer indication. Historical statements about more than 35 countries are not a current worldwide approval list.

Research access through clinical trials or individually authorized expanded access has its own requirements. The October 2026 HHS policy for six peptides does not include Tα1 and does not create a corresponding compounding route for it.

What does thymosin alpha-1 do in the immune system?

Thymosin alpha-1 activates dendritic cells through Toll-like receptor signaling, particularly the MyD88-dependent pathway. This stimulates interleukin-12 production and encourages naive T cells to develop toward a cellular Th1 immune response.

A paper published in Blood in 2004 described this mechanism in defenses against fungal infection. It has also been discussed in relation to intracellular pathogens and the possible restoration of disrupted immune functions involving impaired dendritic cell activation. A demonstrated mechanism alone, however, does not establish a clinical benefit in every such situation. Source 1

Is TB-500 the same as thymosin beta-4?

No. TB-500 is the synthetic, acetylated seven-amino-acid fragment Ac-LKKTETQ, corresponding to positions 17 through 23 of the full 43-amino-acid peptide. Other regions of Tβ4, such as its C-terminal AGES motif, are absent. The biological effects of the complete molecule therefore cannot simply be assigned to the fragment.

The ophthalmic and cardiac data cited here were obtained with full-length thymosin beta-4, not the TB-500 fragment, and cannot be transferred to it. The heart-attack findings described earlier also come mainly from preclinical research.

Removal of TB-500 from FDA Category 2 in April and the nonbinding committee recommendation in July 2026 were not approval. The HHS policy published on October 30, 2026, describes enforcement discretion under narrow conditions for TB-500 acetate administered subcutaneously or intramuscularly. It is neither FDA approval nor final inclusion on the 503A bulks list. Requirements include a patient-specific prescription, a single active ingredient, qualified manufacturing and documented quality testing, and reporting of serious adverse events and product quality problems. It does not broadly cover online products, full-length thymosin beta-4, thymosin alpha-1, or prothymosin alpha. Source 1 Source 2 Source 3

Did thymosin alpha-1 work in the sepsis trials?

An established survival benefit has not been demonstrated; the trials produced different findings. In ETASS, the earlier study of 361 participants published in Critical Care in 2013, 28-day mortality was 26.0% with thymosin alpha-1 versus 35.0% with control treatment. Statistical significance was borderline in the log-rank test, p = 0.049, and was not reached in the primary unstratified analysis, p = 0.062. Source 1

TESTS randomized 1,106 adults; 1,089 entered its modified intention-to-treat analysis. Mortality at 28 days was 23.4% with Tα1 versus 24.1% with placebo. Following the official correction, the hazard ratio is 0.97, with a 95% confidence interval of 0.76 to 1.24. This does not establish a survival benefit. Exploratory subgroup signals, including those in people age 60 or older, need prospective confirmation and should not be treated as confirmed benefits. Source 1 Source 2

What is the thymus, and why does it matter for immunity?

The thymus is a small organ in the upper chest. It trains and matures T lymphocytes before they enter the circulation. It is most active in childhood. After puberty, it gradually shrinks and produces fewer naive T cells with increasing age.

A 2020 review in Immunity and Ageing described this involution as an important driver of age-related immune decline, or immunosenescence. Features include weaker adaptive responses and increased chronic inflammation. The original thymosin research hypothesis was that thymic hormones might partly compensate for the organ’s decline. That idea motivated the extraction and study of thymosin fraction 5 in the 1960s. Source 1

Is thymosin alpha-1 available in the United States?

According to the sources reviewed, Tα1 is not an FDA-approved medicine. Clinical trials or individually authorized expanded access may provide special research access; this is not a promise of routine availability.

The FDA documents withdrawal of Tα1’s nomination and its removal from Category 2 in April 2026. That action alone did not authorize compounding. The later October HHS policy does not include Tα1 either. The sources discussed therefore do not establish a general access route through that policy. Source 1

Where can I find more information about individual thymosin substances?

Separate overviews discuss two of the most frequently debated substances or forms. The thymosin beta-4 overview covers actin biology, cardiac and corneal research, and regulatory status. The TB-500 article explains the synthetic fragment, its FDA compounding classification, and its differences from full-length thymosin beta-4. Source 1 Source 2

This article is for information only and does not replace medical advice, diagnosis, or treatment. According to the sources reviewed on October 31, 2026, none of the thymosin peptides discussed has FDA approval for human use in the United States. Personal medical decisions should be discussed with a qualified healthcare professional.

References und Quellen

Bibliographic names and titles are retained exactly as supplied in the source material. Widersprüchliche Substanzzuordnungen sind in den redaktionellen Prüfhinweisen gekennzeichnet.

Weiterführende Artikel aus dem Ausgangsmaterial: